吉非替尼获得性耐药非小细胞肺癌患者miR-21、miR-155表达水平及临床意义  

The Expression Level and Clinical Significance of miR-21 and miR-155 in Patients with Acquired Drug-resistant Non-small Cell Lung Cancer with Gefitinib

作　　者：胡波 朱琰琰 徐颖 HU Bo;ZHU Yanyan;XU Ying(Henan People's Hospital,Zhengzhou,450000)

机构地区：[1]河南省人民医院,450000 [2]中国人民解放军联勤保障部队第九八八医院,450000

出　　处：《实用癌症杂志》2021年第9期1417-1420,1425,共5页The Practical Journal of Cancer

摘　　要：目的探讨吉非替尼获得性耐药非小细胞肺癌患者miR-21、miR-155表达水平及临床意义。方法选取接受吉非替尼治疗出现耐药的80例晚期NSCLC患者作为研究组,另选取60例吉非替尼治疗效果良好、6个月以上病情无进展NSCLC患者为对照组。采用RT-PCR检测患者组织及血清中miR-21、miR-155表达水平;采用免疫组织化学法检测肺癌组织中EGFR的表达;采用Kaplan-Meier生存曲线比较患者3年内生存情况。结果研究组血清、组织中miR-21水平及血清miR-155水平明显高于对照组(P<0.001),但组织中miR-155水平与对照组相比无统计学差异(P>0.05);EGFR低表达患者血清、组织中miR-21及血清miR-155水平明显高于EGFR高表达患者(P<0.05),而组织中miR-155水平无统计学差异(P>0.05)。生存曲线结果显示血清中miR-21、miR-155高表达患者生存率明显低于低表达患者(χ^(2)=14.179,P<0.001;χ^(2)=18.338,P<0.001);组织中miR-21高表达患者生存率明显低于低表达患者(χ^(2)=12.195,P<0.001),但miR-155高表达患者生存率较低表达患者无统计学差异(χ^(2)=1.162,P>0.05)。结论吉非替尼获得性耐药NSCLC患者血清及组织中miR-21、miR-155水平与患者组织中EGFR水平及预后相关,可能在吉非替尼获得性耐药中发挥作用。Objective To explore the expression levels and clinical significance of miR-21 and miR-155 in patients with acquired drug-resistant non-small cell lung cancer with gefitinib.Methods We selected 80 patients with advanced NSCLC who were treated with gefitinib in our hospital from April 2013 to April 2016 and developed drug resistance as the study group.Another 60 patients with gefitinib treatment with good effect and no disease condition for more than 6 months were selected.Patients with advanced NSCLC served as the control group.RT-PCR was used to detect the expression levels of miR-21 and miR-155 in patients’tissues and serum;immunohistochemistry was used to detect the expression of EGFR in lung cancer tissues;Kaplan-Meier survival curves were used to compare the survival of patients within 3 years.Results The serum and tissue levels of miR-21 and serum miR-155 levels in the study group were significantly higher than those in the control group(P<0.001),but the miR-155 levels in the tissues were not significantly different from those in the control group(P>0.05);EGFR The levels of miR-21 and serum miR-155 in patients with low expression were significantly higher than those with high expression of EGFR(P<0.05),but there was no significant difference in the level of miR-155 in tissues(P>0.05);the survival curve results showed The survival rate of patients with high expression of miR-21 and miR-155 in serum was significantly lower than that of patients with low expression(χ^(2)=14.179,P<0.001;χ^(2)=18.338,P<0.001).The survival rate of patients with high expression of miR-21 in tissues was significantly lower In patients with low expression(χ^(2)=12.195,P<0.001),there was no significant difference in the survival rate of patients with high expression of miR-155 compared with patients with low expression(χ^(2)=1.162,P>0.05).Conclusion The levels of miR-21 and miR-155 in serum and tissues of NSCLC patients with acquired resistance to gefitinib are correlated with the levels of EGFR in the patient's tissues and pro

关 键 词：吉非替尼 获得性耐药 非小细胞肺癌 MIR-21 MIR-155 

分 类 号：R734.2[医药卫生—肿瘤]